Lakefront Announces Sale of Preclinical CAR-T Programs to Armed Cell Therapeutics
Lakefront Biotherapeutics completed the sale of its early-stage CAR-T pipeline to Belgium-based Armed Cell Therapeutics, receiving €8 million upfront plus potential milestones of up to $230 million and a low-single-digit royalty. The divested preclinical assets, originating from the 2022 AboundBio acquisition, are armed CAR-T constructs targeting hematological and solid tumors; the buyer was formed by industry veterans Paul Stoffels, John Mellors and Peter Verhaeghe.
Key figures
- Deal Value Usd
- €8 million upfront plus up to $230 million in milestones and low-single-digit royalty
- Royalty
- low-single-digit
- Upfront payment
- €8 million
- Milestone potential
- $230 million
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.